Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals

Cancer. 2020 Oct 15;126(20):4615-4616. doi: 10.1002/cncr.33110. Epub 2020 Aug 7.

Authors

Lorenzo D'Ambrosio^{1

2}, Saskia Litière³, Silvia Stacchiotti⁴, Alessandro Gronchi⁵

Affiliations

¹ Department of Oncology, University of Turin, Turin, Italy.
² Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
³ Statistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
⁴ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
⁵ Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

PMID: 32767667
DOI: 10.1002/cncr.33110

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Dacarbazine / therapeutic use
Doxorubicin / therapeutic use
Humans
Ifosfamide / adverse effects
Leiomyosarcoma* / drug therapy
Propensity Score
Sarcoma* / drug therapy

Substances

Dacarbazine
Doxorubicin
Ifosfamide